Results for this period
Third quarter1 January 2026 to 30 September 2026Non-consolidated (separate)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Operating profit declined due to a change in the sales mix following lower revenue from genetic testing kits for COVID-19 and an increase in research and development expenses. Revenue edged up year on year, driven by increased demand for influenza-only test kits and other products.
No applicable matters ("There are no applicable matters")
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (separate) |
| Period Covered | 1 January 2026 to 30 September 2026 |
| Net Sales | ¥6,232 million (YoY +0.1%) |
| Operating profit | ¥2,064 million (YoY -5.9%) |
| Ordinary income | ¥2,162 million (YoY -1.0%) |
| Profit attributable to owners of the parent | ¥1,575 million (YoY -0.8%) |
| Net income per share | ¥82.72 |
| Equity ratio | End of the current fiscal period 87.1 / End of previous period 83.5 |
| Total assets | ¥21,069 million |
| Net assets | ¥18,355 million |
| Full-year earnings forecast | Net Sales ¥11,428 million (YoY +1.5%) / Operating profit ¥4,414 million (YoY -5.0%) / Ordinary income ¥4,437 million (YoY -6.3%) / Net income ¥3,220 million (YoY -6.0%) |
| Annual Dividend Forecast | ¥100 → ¥100（0.0%） |
| Depreciation and amortization | ¥209 million |
| Disclosure regarding the going concern assumption | No applicable matters ("There are no applicable matters") |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 19,051,200 shares |
| Treasury Shares at Period-End | 2,550 shares |
| Factors Behind Changes in Business Performance | Operating profit declined due to a change in the sales mix following lower revenue from genetic testing kits for COVID-19 and an increase in research and development expenses. Revenue edged up year on year, driven by increased demand for influenza-only test kits and other products. |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The decline in operating profit was mainly due to a change in the sales mix following lower revenue from genetic testing kits for COVID-19 and an increase in research and development expenses. Revenue increased from influenza-only test kits and other products, but declined from genetic test kits for COVID-19 and the OTC and other businesses.